Sign In  |  Register  |  About San Anselmo  |  Contact Us

San Anselmo, CA
September 01, 2020 1:33pm
7-Day Forecast | Traffic
  • Search Hotels in San Anselmo

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:

Connect Biopharma to Host a Conference Call Tuesday, October 4 to Discuss Topline Results for the Pivotal Trial in China of Lead Candidate, CBP-201, in Patients with Moderate-to-Severe Atopic Dermatitis

Conference call and webcast to take place at 5:30 a.m. PDT/8:30 a.m. EDT,
tomorrow, Tuesday, October 4

SAN DIEGO and TAICANG, SUZHOU, China, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect Biopharma or the Company), a company developing therapeutics for T cell-driven inflammatory diseases, today announced it will report topline results for its pivotal trial in China of lead candidate, CBP-201, in patients with moderate-to-severe atopic dermatitis (AD). Following the press release, the Company will host a webcast and conference call at 5:30 a.m. PDT to discuss these results.

The news release will be posted to the investor relations section of Connect Biopharma’s website at: https://investors.connectbiopharm.com/investors.

About Connect Biopharma Holdings Limited
Connect Biopharma is a U.S. and China-based clinical-stage biopharmaceutical company dedicated to improving the lives of patients with inflammatory diseases through the development of therapies derived from T cell research. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, CBP-201, is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis and asthma. The Company’s second most advanced product candidate, CBP-307, is a modulator of S1P1 T cell receptor and is in development for the treatment of ulcerative colitis (UC). The Company’s third product candidate, CBP-174, is a peripherally acting antagonist of histamine receptor 3, in development for the treatment of pruritus associated with AD. For more information, please visit: https://www.connectbiopharm.com/

IR/PR CONTACTS: 
Ina McGuinness
T: +1 (805) 427-1372
imcguinness@connectpharm.com

 


Primary Logo

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
Copyright © 2010-2020 SanAnselmo.com & California Media Partners, LLC. All rights reserved.